| name | endo-t-cessation-no-response-6mo-safety |
| description | Recommends discontinuing testosterone therapy in women with hypoactive sexual desire disorder (HSDD) who show no symptomatic improvement after a 6‑month trial. Triggers include a clinician reviewing lack of response at follow‑up and considering continuation beyond six months while noting the absence of long‑term safety data. |
Suggest cessation of testosterone if no response by 6 months, noting lack of long-term safety data
STEP 1 — Gather Information
Confirm diagnosis of HSDD, record baseline sexual function (e.g., frequency of satisfying sexual events, desire, distress), document testosterone formulation, dose, start date, and adherence; assess for signs of androgen excess (acne, hirsutism, voice change).
STEP 2 — Rule In / Rule Out
Determine whether the patient has completed at least a 6‑month trial of testosterone at an adequate dose; if yes, proceed to evaluate response; if no, continue the trial or address adherence issues before reassessment.
STEP 3 — Classify or Stratify
Classify the patient as a responder (≥1‑event increase in satisfying sexual activity per month or meaningful reduction in distress) or non‑responder (no appreciable improvement in desire, arousal, orgasm, or distress despite adequate therapy).
STEP 4 — Decide
For non‑responders, suggest cessation of testosterone therapy, discuss the lack of safety and efficacy data beyond 24 months, and explore alternative non‑hormonal or psychosocial interventions.
Clinical Guardrails / Mimics / Pitfalls
Do not continue testosterone solely because of hope of future benefit; avoid ignoring emerging androgenic adverse effects; do not prescribe for indications other than HSDD (e.g., fatigue, mood, cognition); remember that long‑term safety (>24 months) is unknown, so prolonged use without clear benefit poses uncertain risk.
Concrete Clinical Example
A 58‑year‑old postmenopausal woman with HSDD used transdermal testosterone 300 µg/day for 6 months; her diary showed no change in satisfying sexual events (still 1–2/month) and persistent distress. Serum testosterone was within the target range. The clinician stopped therapy, reviewed the absence of long‑term safety data, and referred her for cognitive‑behavioral sex therapy.
Source: Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2260
